生物活性 | |||
---|---|---|---|
靶点 |
|
||
描述 | PCI-34051 is an inhibitor of pure recombinant HDAC8, exhibits a Ki of 10 nM, demonstrating >200-fold selectivity over other tested HDACs, including HDACs 1, 2, 3, 6, and 10. Derived from a low molecular weight hydroxamic acid scaffold, PCI-34051 initially possessed promising potency (HDAC8; Ki=2 μM) and selectivity (approximately fivefold) for HDAC8 relative to other class I HDACs. In cell lines derived from T-cell lymphomas, such as Jurkat and HuT78, PCI-34051 induces apoptosis at low micromolar concentrations, while doses as high as 20 μM have no effect on B-cell- or myeloid-derived lymphomas or solid tumor lines [1]. |
细胞研究 | |||||
---|---|---|---|---|---|
细胞系 | 浓度 | 检测类型 | 检测时间 | 活动说明 | 数据源 |
human Huh7 cells | Function assay | 3 days | Antiviral activity against HCV genotype 1b infected in human Huh7 cells after 3 days by luciferase reporter gene assay, EC50=1.8 μM | 25490700 | |
human Jurkat cells | Growth inhibition assay | 72 h | Growth inhibition of human Jurkat cells incubated for 72 hrs by MTS assay, GI50=11 μM | 23116147 | |
human MT2 cells | Growth inhibition assay | 72 h | Growth inhibition of human MT2 cells incubated for 72 hrs by MTS assay, GI50=15 μM | 23116147 |
实验方案 | |||
---|---|---|---|
1mg | 5mg | 10mg | |
1 mM 5 mM 10 mM |
3.37mL 0.67mL 0.34mL |
16.87mL 3.37mL 1.69mL |
33.75mL 6.75mL 3.37mL |
参考文献 |
---|